Issue link: https://www.e-digitaleditions.com/i/1199406
Tablets & Capsules January 2020 9 billion by the end of 2025 with a compound annual growth rate of 5.1 percent, according to a report by QY Research. The European region is the largest consumer of pharma- ceutical equipment, though China's consumption is projected to have a higher growth rate. Key manufactur- ers include GE Healthcare, Siemens, Bosch (now Syntegon), Sartorius, Shimadzu, Shinwa, ACG, Tofflon, Bausch+Stroebel, GE A, Tr uking, Chinasun, Bohle, Sejong Pharmat- ech, and SK Group. Demand for generics will spur growth in oral controlled-release market VALLEY COTTAGE, NY—Ris- ing access to healthcare facilities is driving an increase in generic drug product consumption, fueling the need solid oral controlled-release dosage products, according to a report by Future Market Insights. T he large-scale requirement for anti-hypertensive drug products is likely to boost the market growth to a great extent. The dissolution controlled-release system segment is projected to hold a 50 percent share of the market by 2027. Pharmaceuticals to increase guar complex consumption ALBANY, NY—A report by Trans- parency Market Research forecasts the global guar complex products market to reach $1.7 billion by the end of 2026, representing a com- pound annual growth rate of 2.6 per- cent. The pharmaceutical sector is projected to be the fastest-growing end-user industry for guar complex, growing at a compound annual rate of 5.3 percent through the fore- cast period. Leading manufacturers include Vikas, Jai Bharat Gum, Shree Ram Gum, Hindustan Gums, Car- gill, Ashland, Lucid, India Glycols, Supreme Gums, Lamberti, and Rama. Vitamin B6 market to reach $740 million by 2025 DEERFIELD BEACH, FL —The global vitamin B6 (pyridoxine hydro- chloride) market is expected to be valued at $740 million by the end of 2025, growing at a compound annual rate of 8.9 percent according to a report by ReportsBuzz. Vitamin B6 is widely used in the animal nutrition, food and beverage, and pharmaceu- tical industries. The report identi- fies Tianxin Pharmaceutical, DSM, Huazhong Pharmaceutical, Hegno, and Guangji Pharmaceutical as major market players. industry news FDA launches clinical outcome platform SILVER SPRING, MD—The FDA has launched an internet-based plat- form called Cure ID that allows pro- fessionals in the clinical community to use the website, a smartphone, or other mobile device to report their experiences treating infectious dis- eases using existing FDA-approved drugs in novel ways. The platform capt ures clinical outcomes when drugs are used for new indications, populations, doses, and /or combi- nations, facilitating crowdsourcing of medical information from health- car e provider s to g uide poten- tially life-saving interventions and the development of new drugs for neglected diseases. The platform is a result of a collaboration between the FDA and the National Center for Advancing Translational Sci- ences (NCATS), which is part of the National Institutes of Health (NIH). FDA publishes 105 PSGs SILVER SPRING, MD—In Nov- ember, the FDA published 105 prod- uct-specific guidances (PSGs), which provide recommendations for devel- oping generic drugs and generat- ing the evidence needed to support A N DA approval. T he published guidances include revisions of previ- ous PSGs as well as new guidances for complex products, products with no currently approved ANDAs, and complex and non-complex NCEs. The new batch brings the total num- ber of PSGs to more than 1,750.